Home › Upcoming votes › Ensysce Biosciences, Inc.
Prior-year votes at Ensysce Biosciences, Inc. → 2025-2026 season, in the search
Read the proxy statement on EDGAR
Summary, checked against the proxy statement. Each point is backed by a passage of the filing, shown under the point; figures under “Last year’s votes” come from the company’s Form 8-K. Read the proxy statement before relying on it.
Virtual annual meeting with nine proposals: a Series C conversion share issuance, a reverse stock split, more authorized shares, an equity plan increase, two directors, say-on-pay and frequency, auditor and adjournment.
“Nasdaq has advised the Company that it must comply with Nasdaq initial listing requirements because of a Nasdaq determination that a change of control will occur with the issuance of shares of Common stock upon conversion of the Series C Preferred Stock.” Find it in the filing
“the potential issuance of up to 433,907 shares of Series C Preferred Stock would, upon conversion, total 433,907,000 shares of Common Stock.” Find it in the filing
“James Morrison, who became President of the Company and a Director immediately following the Merger, will be appointed as our Chief Executive Officer following the Annual Meeting.” Find it in the filing
“Mr. Morrison would have beneficial ownership of approximately 41.0% of the shares of Common Stock outstanding if the Series C Preferred Stock were converted as of the date hereof.” Find it in the filing
“Nasdaq staff provided an additional 180 calendar day extension, or until February 22, 2027, to regain compliance.” Find it in the filing
“revise the total number of shares of Common Stock that the Company is authorized to issue from 250,000,000 to 500,000,000” Find it in the filing
“solely to increase the aggregate number of shares of Common Stock that may be issued under the Plan from 950,206 pre-Reverse Stock Split shares to 1,500,000 post Reverse Stock Split shares.” Find it in the filing
“"FOR" Proposal 6, "FOR" Proposal 7 with a three-year recommendation” Find it in the filing
“solely to increase the aggregate number of shares of Common Stock that may be issued under the Plan from 950,206 pre-Reverse Stock Split shares to 1,500,000 post Reverse Stock Split shares.” Find it in the filing
Last year’s proxy statement, page 2: “increase the aggregate number of shares of the Company's common stock that may be issued under the plan from 121,457 shares to 721,457 shares”
“To approve, for purposes of complying with Nasdaq Listing Rules 5635(a) and 5635(b), the full issuance of shares of the Company's common stock ("Common Stock") issuable upon conversion of the Company's Series C Preferred Stock” Find it in the filing
Last year’s proxy statement, page 2: “To approve, for purposes of complying with Nasdaq Listing Rule 5635(d), the full issuance of shares of common stock and exercise of warrants for common stock issued by the Company to an investor”
“To approve, on an advisory basis, the frequency of advisory votes on the compensation of the Company's named executive officers” Find it in the filing
Last year’s proxy statement, page 2: “The Board of Directors recommends that stockholders vote "FOR" each of Proposal 1, Proposal 2, Proposal 3, Proposal 4 and the Additional Solicitation Proposal.”
“Lynn Kirkpatrick, immediately following the Annual Meeting, will resign as Chief Executive Officer and serve as Chief Operating Officer.” Find it in the filing
Ballot read from the proxy statement and checked. As listed in Ensysce Biosciences, Inc.’s proxy statement, with the board’s recommendation on each item. The company has filed 1 set of additional materials since; they can add to or change what is below, so check them before relying on it.
| # | Item | Proposed by | Board recommends | Last year (same kind of item) |
|---|---|---|---|---|
| 1 | Approve full issuance of common stock upon conversion of Series C Preferred Stock (Nasdaq Rules 5635(a) and 5635(b)) | Board | For | — |
| 2 | Charter amendment to effect a reverse stock split (1-for-10 to 1-for-30) | Board | For | — |
| 3 | Charter amendment to increase authorized common stock from 250,000,000 to 500,000,000 shares | Board | For | — |
| 4 | Amendment to the Amended and Restated 2021 Omnibus Incentive Plan to increase shares | Board | For | — |
| 5 | Election of two Class II directors Director election |
Board | For | 2 nominees; support 70% to 70% |
| 6 | Advisory vote on named executive officer compensation Say on pay |
Board | For | — |
| 7 | Advisory vote on frequency of say-on-pay votes Say-on-pay frequency |
Board | 3 years | — |
| 8 | Ratification of Baker Tilly US, LLP as independent registered public accounting firm for 2026 Auditor |
Board | For | 94% support |
| 9 | Adjournment proposal Adjournment |
Board | For | — |
From Ensysce Biosciences, Inc.’s Form 8-K, filed January 8, 2026, for the meeting held January 7, 2026 (read it on EDGAR). Support is the share of votes cast that were FOR: abstentions and broker non-votes are left out.
| Item | Support (of votes cast) | Reported outcome |
|---|---|---|
| The stockholders approved, for purposes of complying with Nasdaq Listing Rule 5635(d), the full issuance of shares of common stock and exerc | 73% | Approved |
| 2. The amendment of the Ensysce Biosciences, Inc | 60% | Approved |
| Elect Director: William Chang | 70% | — |
| Elect Director: Lee Rauch | 70% | — |
| 4. The appointment of Baker Tilly US, LLP as the Company's independent registered public accounting firm for the fiscal year ending December | 94% | Approved |
The meeting facts and ballot come from the SEC proxy filings listed above. Ballots are read from the proxy statement and checked against the filing’s own text; when that check does not pass, the page shows “see the proxy statement” instead of a ballot. Last year’s figures are the company’s official Form 8-K results and the managers’ Form N-PX reports. Nothing on this page predicts how any shareholder will vote, and it is not investment advice. How this works.